Raymond James & Associates Ascendis Pharma A/S Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Raymond James & Associates holds 4,135 shares of ASND stock, worth $598,003. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,135
Previous 4,132
0.07%
Holding current value
$598,003
Previous $624,000
9.78%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ASND
# of Institutions
223Shares Held
56.5MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.46 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$718 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$621 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$607 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$567 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.07B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...